Diligence memo · auto-generated · as of July 2, 2026
Permeon Biologics, Inc.
Permeon Biologics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Permeon Biologics, Inc. operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Permeon Biologics, Inc. has raised $6.0M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.5M on 2010-11-23.
Most recent recorded round closed around 2011-12-19.
Valuation (modeled)modeled
Provath models Permeon Biologics, Inc. at approximately $95M (range $1.9M–$746M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.59× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 14.5 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 45% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 54% of those peers.
Closest niche peers: First China Pharmaceutical Group, Inc., MediQuest Holdings LLC, Ampla Pharmaceuticals Inc, Biomimetix Pharmaceutical, Inc., Prexa Pharmaceuticals Inc.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.